For J&J, there was a positive outcome as the Oncologic Drugs Advisory Committee (ODAC) voted six to two in favour of approval ...

The ODAC cited concerns with patient populations in clinical trials used to support the proposed expansion. Johnson & Johnson ...

This composite flow cytometric panel illustrates the bone marrow of a newly diagnosed primary plasma cell leukemia patient demonstrating CD38 +, λ-a-restricted, CD20-plasma cells.

In September 2021, the Center for Drug Evaluation (CDE) of China proclaimed that Roche’s CD3/CD20 bispecific antibody RO7030816 (Mosunetuzumab) received clinical trial implied permission for the ...

In all, 88% of participants achieved a complete response with CD20-CD19-directed therapy. Additionally, every patient received their treatment within 8 to 12 days of starting lymphodepletion.

The business is stopping further research on imvotamab, a CD20 x CD3 bispecific antibody, and IGM-2644, a CD38 x CD3 bispecific antibody. Phase 1b rheumatoid arthritis and systemic lupus ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...